

TRIAL RESULTS – 16th FEBRUARY 2022

[ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma](#)

"These groundbreaking results are important for patients with advanced classical Hodgkin lymphoma given that an improvement in overall survival has rarely been shown in frontline treatment of this disease," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "We look forward to presentation of the results at an upcoming medical meeting."

[Ph 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in PFS in Patients with Advanced or Recurrent Endometrial Cancer](#)

"As an oral, chemotherapy-free treatment, selinexor has the potential to transform the way advanced or recurrent endometrial cancer is treated and I am intrigued to learn more about the patients with the wild-type p53," said Professor Ignace Vergote, principal investigator and gynecologist oncologist, ENGOT and the Belgium and Luxembourg Gynaecological Oncology Group (BGOG), University of Leuven, Leuven Cancer Institute, Leuven, Belgium. "This study brings us one step closer to offering patients a treatment option that can give them more time with their friends and families."

[Pivotal Ph 3 Data for KEYTRUDA® in High-Risk Early-Stage TNBC Published in the New England Journal of Medicine](#)

"These data, which supported the FDA approval and updates to the NCCN guidelines, establish that KEYTRUDA plus chemotherapy as neoadjuvant therapy followed by adjuvant KEYTRUDA could change clinical practice for the treatment of patients with high-risk early-stage TNBC," said Dr. Peter Schmid, lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute in London, England. "KEYNOTE-522 is the first prospective randomized Phase 3 trial to show an improvement in event-free survival among patients with stage II and stage III TNBC."

[Positive Preliminary Ph 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Announced](#)

"The responses observed with EG-70 are an important step towards NMIBC patients avoiding radical cystectomy," said Dr. Gary Steinberg, Professor and Director at the Perlmutter Cancer Center and Department of Urology Goldstein Urology Bladder Cancer Program of NYU Langone Health, and lead Principal Investigator for the LEGEND study. "If similar results are observed as the study progresses, I am confident that this novel intravesical monotherapy will make a meaningful impact in the lives of patients with high risk NMIBC."